Lactate-Driven HMGB1 Modification and Exosomal Release in Sepsis: Mechanistic Insights and Research Implications

Study Background and Research Question

Sepsis remains a critical medical challenge, characterized by an overwhelming dysregulation of the host's inflammatory response to infection, often culminating in organ dysfunction. Elevated serum lactate and high mobility group box-1 (HMGB1) levels are both recognized as adverse prognostic markers in sepsis, correlating strongly with severity and mortality. While lactate is widely used to guide sepsis management, its mechanistic role in modulating inflammatory mediators like HMGB1 has remained unclear. The reference study (Yang et al., 2022) directly addresses whether lactate is not just a biomarker but also a driver of pathological HMGB1 release during polymicrobial sepsis.

Key Innovation from the Reference Study

The principal innovation of this work lies in the identification of lactate as an active modulator of post-translational modifications on HMGB1, specifically lactylation and acetylation, which facilitate its exosomal release from macrophages. The study provides evidence that extracellular lactate, taken up via monocarboxylate transporters (MCTs), drives these modifications through distinct signaling cascades—p300/CBP-dependent lactylation and Hippo/YAP-mediated suppression of SIRT1, coupled with GPR81 and β-arrestin2-related pathways for acetylation. This mechanistic insight represents a significant advance in our understanding of how metabolic changes can alter inflammatory signaling at the molecular level in sepsis.

Methods and Experimental Design Insights

Yang et al. employed a multi-tiered experimental approach combining in vivo and in vitro models. Key elements included:

• Use of wild-type and genetically engineered mice (including macrophage-specific YAP knockout models) subjected to cecal ligation and puncture (CLP) to induce polymicrobial sepsis.
• Isolation of peritoneal macrophages and stimulation with exogenous lactate to assess HMGB1 modification and release.
• Pharmacological interventions targeting lactate production, GPR81 signaling, and associated acetyltransferases.
• Quantification of HMGB1 levels in serum exosomes and assessment of endothelial barrier function upon exposure to exosomal HMGB1.
• Molecular analyses (e.g., PCR genotyping, immunoblotting, immunoprecipitation) to characterize post-translational modifications and track intracellular localization of HMGB1.

This integrative design allowed the authors to dissect both the upstream metabolic cues and the downstream consequences for inflammatory signaling and vascular barrier integrity.

Protocol Parameters

• CLP-induced polymicrobial sepsis: Perform cecal ligation and puncture in adult mice to model septic conditions and monitor survival outcomes.
• Macrophage isolation and stimulation: Use peritoneal lavage to collect macrophages; stimulate with 10–20 mM sodium lactate in vitro to induce post-translational modifications.
• Inhibitor pretreatment: Apply specific lactate production inhibitors or GPR81 antagonists prior to septic challenge to evaluate their impact on HMGB1 release.
• Genetic knockout strategies: Cross YAP floxed mice with Lyz2-Cre to generate macrophage-specific YAP deletions, confirmed by PCR analysis.
• Exosome isolation and quantification: Collect serum; isolate exosomes via ultracentrifugation and assess HMGB1 content by western blot or ELISA.
• Endothelial permeability assays: Expose cultured endothelium to isolated exosomal HMGB1 and evaluate barrier integrity using transwell assays or tracer flux measurements.

Core Findings and Why They Matter

Several pivotal discoveries emerge from this research (Yang et al., 2022):

• Lactate actively modifies HMGB1: Macrophages exposed to increased extracellular lactate exhibit enhanced HMGB1 lactylation and acetylation. These modifications are mediated by distinct pathways—lactylation via p300/CBP, and acetylation via both suppression of SIRT1 by Hippo/YAP and recruitment of acetylases by GPR81/β-arrestin2.
• Exosomal release of HMGB1: The doubly-modified HMGB1 is preferentially packaged into exosomes and secreted by macrophages, rather than via passive release mechanisms.
• Endothelial impact: Circulating exosomal HMGB1 markedly increases vascular permeability, providing a mechanistic link to the vascular leakage and organ dysfunction characteristic of severe sepsis.
• Therapeutic modulation: Inhibition of lactate production or GPR81 signaling (genetically or pharmacologically) reduces circulating exosomal HMGB1 and improves survival in septic mice, suggesting that targeting metabolic-inflammation crosstalk may have clinical benefit.

These findings deepen our understanding of the intersection between cellular metabolism and inflammatory signaling, indicating that metabolites like lactate can function as upstream effectors in the inflammation-apoptosis axis relevant to sepsis pathogenesis.

Comparison with Existing Internal Articles

Previous internal resources have focused on the utility of IKK inhibitors such as Bay 11-7821 (BAY 11-7082) in inflammatory signaling pathway research and cancer biology. These reviews ("Selective IKK Inhibitor for NF-κB Pathway Research"; "Reliable IKK Inhibition for Inflammatory Pathway Research") have highlighted how NF-κB pathway inhibitors can dissect molecular inflammatory responses and apoptosis regulation. The present study, while not directly using IKK inhibitors, complements this literature by elucidating upstream metabolic triggers (lactate) that promote inflammatory mediator release and could synergize with NF-κB pathway inhibition. Thus, combining metabolic modulation with pathway-specific inhibitors like Bay 11-7821 represents a rational strategy in advanced inflammatory and cancer research workflows.

Limitations and Transferability

While Yang et al. provide strong evidence for lactate-driven HMGB1 modification and exosomal release in murine sepsis models, several considerations temper the immediate translational impact:

• Species specificity: The mechanisms were demonstrated in mouse models and primary murine macrophages; validation in human systems is needed for clinical extrapolation.
• Complexity of in vivo sepsis: Sepsis is multifactorial, and while lactate/HMGB1 crosstalk is important, additional mediators and pathways play significant roles in patient outcomes.
• Targeting metabolic pathways: Therapeutic modulation of lactate production or signaling must be balanced against potential systemic metabolic effects.

Despite these limitations, the study provides a robust framework for further exploration of metabolic-inflammation links in both preclinical and translational settings.

Why this cross-domain matters, maturity, and limitations

The bridge between metabolic regulation (lactate signaling) and inflammatory mediator release enriches the field of inflammatory signaling pathway research and has implications for apoptosis regulation study, especially in the context of sepsis, cancer, and immune modulation. The mechanistic maturity is supported in animal models, but full clinical transferability awaits further validation.

Research Support Resources

For researchers aiming to investigate crosstalk between metabolic cues and inflammatory pathways, selective inhibitors of key signaling molecules remain indispensable. Bay 11-7821 (BAY 11-7082) (SKU A4210) from APExBIO is a well-characterized IKK inhibitor that blocks NF-κB activation and has been widely adopted in both inflammation and apoptosis regulation studies. Its use may complement metabolic modulation strategies, as outlined in the current reference, to further dissect the molecular interplay underlying macrophage activation, exosomal signaling, and endothelial dysfunction.